Synthesis and activity of fibrillogenesis peptide inhibitors related to the 17–21 β-amyloid sequence
Peptide derivatives 1– 5, incorporating synthetic non-proteinogenic amino acids, related to the β-amyloid 17–21 fragment of the amyloidogenic Aβ 1–40, and the N-protected decapeptide 6, corresponding to a dimeric sequence of the same fragment, have been synthesized. These compounds were designed by...
Gespeichert in:
Veröffentlicht in: | European journal of medicinal chemistry 2009, Vol.44 (1), p.179-189 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 189 |
---|---|
container_issue | 1 |
container_start_page | 179 |
container_title | European journal of medicinal chemistry |
container_volume | 44 |
creator | Giordano, Cesare Masi, Annalisa Pizzini, Aldo Sansone, Anna Consalvi, Valerio Chiaraluce, Roberta Lucente, Gino |
description | Peptide derivatives
1–
5, incorporating synthetic non-proteinogenic amino acids, related to the β-amyloid 17–21 fragment of the amyloidogenic Aβ
1–40, and the
N-protected decapeptide
6, corresponding to a dimeric sequence of the same fragment, have been synthesized. These compounds were designed by using Soto's pentapeptide Ac–LPFFD–NH
2 (iAβ5p) as lead compound. Their activity as inhibitors of fibrillogenesis and stability against enzymatic degradation have been determined. Compounds
1,
5 and
6 are potent inhibitors in comparison to the lead compound. Exposure to chymotrypsin of peptide derivatives
1–
5, all containing unnatural amino acids, shows increased stability as compared with iAβ5p and
6. Conformational properties of the new compounds have been determined by CD and FT-IR spectroscopies.
[Display omitted] Synthesis, properties and activity of novel analogues (
1–
6) of the known Ac–Leu-Pro-Phe-Phe-Asp(OH)–NH
2 (iAβ5p) fibrillogenesis pentapeptide inhibitor are reported. |
doi_str_mv | 10.1016/j.ejmech.2008.03.036 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66785592</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523408001657</els_id><sourcerecordid>66785592</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-54e6a302f9ea0a9b463e3ad1b3ae59a6bf8bb9455c20ae7368fc142dfa1d48123</originalsourceid><addsrcrecordid>eNp9kM-KFDEQh4Mo7rj6BiK56K3HStJJd18EWdY_sOBBPYfqpHonQ3dnTDILc_MdfBMfxIfwSezZGfQmFNShvvpV8TH2XMBagDCvt2vaTuQ2awnQrkEtZR6wlWhMWymp64dsBVKqSktVX7AnOW8BQBuAx-xCtBpE1-kVu_18mMuGcsgcZ8_RlXAXyoHHgQ-hT2Ec4y3N9_Md7UrwxMO8CX0oMWWeaMRCnpfIlxAumt_ff0jBf_2scDqMMXie6dueZkdP2aMBx0zPzv2SfX13_eXqQ3Xz6f3Hq7c3lVMdlErXZFCBHDpCwK6vjSKFXvQKSXdo-qHt-67W2klAapRpBydq6QcUvm6FVJfs1Sl3l-JyORc7hexoHHGmuM_WmKbVujuC9Ql0KeacaLC7FCZMByvAHgXbrT0JtkfBFtRSZll7cc7f9xP5f0tnowvw8gxgdjgOCWcX8l9OCmiEuQ96c-JosXEXKNnswtGUD4lcsT6G_3_yB5FKnco</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66785592</pqid></control><display><type>article</type><title>Synthesis and activity of fibrillogenesis peptide inhibitors related to the 17–21 β-amyloid sequence</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Giordano, Cesare ; Masi, Annalisa ; Pizzini, Aldo ; Sansone, Anna ; Consalvi, Valerio ; Chiaraluce, Roberta ; Lucente, Gino</creator><creatorcontrib>Giordano, Cesare ; Masi, Annalisa ; Pizzini, Aldo ; Sansone, Anna ; Consalvi, Valerio ; Chiaraluce, Roberta ; Lucente, Gino</creatorcontrib><description>Peptide derivatives
1–
5, incorporating synthetic non-proteinogenic amino acids, related to the β-amyloid 17–21 fragment of the amyloidogenic Aβ
1–40, and the
N-protected decapeptide
6, corresponding to a dimeric sequence of the same fragment, have been synthesized. These compounds were designed by using Soto's pentapeptide Ac–LPFFD–NH
2 (iAβ5p) as lead compound. Their activity as inhibitors of fibrillogenesis and stability against enzymatic degradation have been determined. Compounds
1,
5 and
6 are potent inhibitors in comparison to the lead compound. Exposure to chymotrypsin of peptide derivatives
1–
5, all containing unnatural amino acids, shows increased stability as compared with iAβ5p and
6. Conformational properties of the new compounds have been determined by CD and FT-IR spectroscopies.
[Display omitted] Synthesis, properties and activity of novel analogues (
1–
6) of the known Ac–Leu-Pro-Phe-Phe-Asp(OH)–NH
2 (iAβ5p) fibrillogenesis pentapeptide inhibitor are reported.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2008.03.036</identifier><identifier>PMID: 18501995</identifier><identifier>CODEN: EJMCA5</identifier><language>eng</language><publisher>Kidlington: Elsevier Masson SAS</publisher><subject>Aggregation inhibitor ; Alzheimer's disease ; Amino Acid Sequence ; Amyloid - antagonists & inhibitors ; Amyloid beta-Peptides - antagonists & inhibitors ; Biological and medical sciences ; Drug Design ; Drug Stability ; Fibrillogenesis ; Fluorescence assay ; Humans ; Medical sciences ; Molecular Conformation ; Neuropharmacology ; Peptide Fragments - antagonists & inhibitors ; Peptide Fragments - chemical synthesis ; Pharmacology. Drug treatments ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Scanning electron microscopy ; Structure-Activity Relationship ; β-Amyloid</subject><ispartof>European journal of medicinal chemistry, 2009, Vol.44 (1), p.179-189</ispartof><rights>2008 Elsevier Masson SAS</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-54e6a302f9ea0a9b463e3ad1b3ae59a6bf8bb9455c20ae7368fc142dfa1d48123</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejmech.2008.03.036$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,4024,27923,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21071636$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18501995$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giordano, Cesare</creatorcontrib><creatorcontrib>Masi, Annalisa</creatorcontrib><creatorcontrib>Pizzini, Aldo</creatorcontrib><creatorcontrib>Sansone, Anna</creatorcontrib><creatorcontrib>Consalvi, Valerio</creatorcontrib><creatorcontrib>Chiaraluce, Roberta</creatorcontrib><creatorcontrib>Lucente, Gino</creatorcontrib><title>Synthesis and activity of fibrillogenesis peptide inhibitors related to the 17–21 β-amyloid sequence</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>Peptide derivatives
1–
5, incorporating synthetic non-proteinogenic amino acids, related to the β-amyloid 17–21 fragment of the amyloidogenic Aβ
1–40, and the
N-protected decapeptide
6, corresponding to a dimeric sequence of the same fragment, have been synthesized. These compounds were designed by using Soto's pentapeptide Ac–LPFFD–NH
2 (iAβ5p) as lead compound. Their activity as inhibitors of fibrillogenesis and stability against enzymatic degradation have been determined. Compounds
1,
5 and
6 are potent inhibitors in comparison to the lead compound. Exposure to chymotrypsin of peptide derivatives
1–
5, all containing unnatural amino acids, shows increased stability as compared with iAβ5p and
6. Conformational properties of the new compounds have been determined by CD and FT-IR spectroscopies.
[Display omitted] Synthesis, properties and activity of novel analogues (
1–
6) of the known Ac–Leu-Pro-Phe-Phe-Asp(OH)–NH
2 (iAβ5p) fibrillogenesis pentapeptide inhibitor are reported.</description><subject>Aggregation inhibitor</subject><subject>Alzheimer's disease</subject><subject>Amino Acid Sequence</subject><subject>Amyloid - antagonists & inhibitors</subject><subject>Amyloid beta-Peptides - antagonists & inhibitors</subject><subject>Biological and medical sciences</subject><subject>Drug Design</subject><subject>Drug Stability</subject><subject>Fibrillogenesis</subject><subject>Fluorescence assay</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Molecular Conformation</subject><subject>Neuropharmacology</subject><subject>Peptide Fragments - antagonists & inhibitors</subject><subject>Peptide Fragments - chemical synthesis</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Scanning electron microscopy</subject><subject>Structure-Activity Relationship</subject><subject>β-Amyloid</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM-KFDEQh4Mo7rj6BiK56K3HStJJd18EWdY_sOBBPYfqpHonQ3dnTDILc_MdfBMfxIfwSezZGfQmFNShvvpV8TH2XMBagDCvt2vaTuQ2awnQrkEtZR6wlWhMWymp64dsBVKqSktVX7AnOW8BQBuAx-xCtBpE1-kVu_18mMuGcsgcZ8_RlXAXyoHHgQ-hT2Ec4y3N9_Md7UrwxMO8CX0oMWWeaMRCnpfIlxAumt_ff0jBf_2scDqMMXie6dueZkdP2aMBx0zPzv2SfX13_eXqQ3Xz6f3Hq7c3lVMdlErXZFCBHDpCwK6vjSKFXvQKSXdo-qHt-67W2klAapRpBydq6QcUvm6FVJfs1Sl3l-JyORc7hexoHHGmuM_WmKbVujuC9Ql0KeacaLC7FCZMByvAHgXbrT0JtkfBFtRSZll7cc7f9xP5f0tnowvw8gxgdjgOCWcX8l9OCmiEuQ96c-JosXEXKNnswtGUD4lcsT6G_3_yB5FKnco</recordid><startdate>2009</startdate><enddate>2009</enddate><creator>Giordano, Cesare</creator><creator>Masi, Annalisa</creator><creator>Pizzini, Aldo</creator><creator>Sansone, Anna</creator><creator>Consalvi, Valerio</creator><creator>Chiaraluce, Roberta</creator><creator>Lucente, Gino</creator><general>Elsevier Masson SAS</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2009</creationdate><title>Synthesis and activity of fibrillogenesis peptide inhibitors related to the 17–21 β-amyloid sequence</title><author>Giordano, Cesare ; Masi, Annalisa ; Pizzini, Aldo ; Sansone, Anna ; Consalvi, Valerio ; Chiaraluce, Roberta ; Lucente, Gino</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-54e6a302f9ea0a9b463e3ad1b3ae59a6bf8bb9455c20ae7368fc142dfa1d48123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aggregation inhibitor</topic><topic>Alzheimer's disease</topic><topic>Amino Acid Sequence</topic><topic>Amyloid - antagonists & inhibitors</topic><topic>Amyloid beta-Peptides - antagonists & inhibitors</topic><topic>Biological and medical sciences</topic><topic>Drug Design</topic><topic>Drug Stability</topic><topic>Fibrillogenesis</topic><topic>Fluorescence assay</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Molecular Conformation</topic><topic>Neuropharmacology</topic><topic>Peptide Fragments - antagonists & inhibitors</topic><topic>Peptide Fragments - chemical synthesis</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Scanning electron microscopy</topic><topic>Structure-Activity Relationship</topic><topic>β-Amyloid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giordano, Cesare</creatorcontrib><creatorcontrib>Masi, Annalisa</creatorcontrib><creatorcontrib>Pizzini, Aldo</creatorcontrib><creatorcontrib>Sansone, Anna</creatorcontrib><creatorcontrib>Consalvi, Valerio</creatorcontrib><creatorcontrib>Chiaraluce, Roberta</creatorcontrib><creatorcontrib>Lucente, Gino</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giordano, Cesare</au><au>Masi, Annalisa</au><au>Pizzini, Aldo</au><au>Sansone, Anna</au><au>Consalvi, Valerio</au><au>Chiaraluce, Roberta</au><au>Lucente, Gino</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis and activity of fibrillogenesis peptide inhibitors related to the 17–21 β-amyloid sequence</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2009</date><risdate>2009</risdate><volume>44</volume><issue>1</issue><spage>179</spage><epage>189</epage><pages>179-189</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><coden>EJMCA5</coden><abstract>Peptide derivatives
1–
5, incorporating synthetic non-proteinogenic amino acids, related to the β-amyloid 17–21 fragment of the amyloidogenic Aβ
1–40, and the
N-protected decapeptide
6, corresponding to a dimeric sequence of the same fragment, have been synthesized. These compounds were designed by using Soto's pentapeptide Ac–LPFFD–NH
2 (iAβ5p) as lead compound. Their activity as inhibitors of fibrillogenesis and stability against enzymatic degradation have been determined. Compounds
1,
5 and
6 are potent inhibitors in comparison to the lead compound. Exposure to chymotrypsin of peptide derivatives
1–
5, all containing unnatural amino acids, shows increased stability as compared with iAβ5p and
6. Conformational properties of the new compounds have been determined by CD and FT-IR spectroscopies.
[Display omitted] Synthesis, properties and activity of novel analogues (
1–
6) of the known Ac–Leu-Pro-Phe-Phe-Asp(OH)–NH
2 (iAβ5p) fibrillogenesis pentapeptide inhibitor are reported.</abstract><cop>Kidlington</cop><pub>Elsevier Masson SAS</pub><pmid>18501995</pmid><doi>10.1016/j.ejmech.2008.03.036</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0223-5234 |
ispartof | European journal of medicinal chemistry, 2009, Vol.44 (1), p.179-189 |
issn | 0223-5234 1768-3254 |
language | eng |
recordid | cdi_proquest_miscellaneous_66785592 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Aggregation inhibitor Alzheimer's disease Amino Acid Sequence Amyloid - antagonists & inhibitors Amyloid beta-Peptides - antagonists & inhibitors Biological and medical sciences Drug Design Drug Stability Fibrillogenesis Fluorescence assay Humans Medical sciences Molecular Conformation Neuropharmacology Peptide Fragments - antagonists & inhibitors Peptide Fragments - chemical synthesis Pharmacology. Drug treatments Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Scanning electron microscopy Structure-Activity Relationship β-Amyloid |
title | Synthesis and activity of fibrillogenesis peptide inhibitors related to the 17–21 β-amyloid sequence |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T01%3A38%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20and%20activity%20of%20fibrillogenesis%20peptide%20inhibitors%20related%20to%20the%2017%E2%80%9321%20%CE%B2-amyloid%20sequence&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Giordano,%20Cesare&rft.date=2009&rft.volume=44&rft.issue=1&rft.spage=179&rft.epage=189&rft.pages=179-189&rft.issn=0223-5234&rft.eissn=1768-3254&rft.coden=EJMCA5&rft_id=info:doi/10.1016/j.ejmech.2008.03.036&rft_dat=%3Cproquest_cross%3E66785592%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66785592&rft_id=info:pmid/18501995&rft_els_id=S0223523408001657&rfr_iscdi=true |